TG Therapeutics, Inc. (TGTX) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Catalyst Pharmaceuticals, Inc.

Springworks Therapeutics, Inc.

TG Therapeutics, Inc.

Taro Pharmaceutical Industries Ltd.

IDEAYA Biosciences, Inc.

Agios Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc.

CureVac NV

Pacira Biosciences, Inc.

Why is TG Therapeutics, Inc. ?

Poor Management Efficiency with a low ROE of 8.40%

The company has been able to generate a Return on Equity (avg) of 8.40% signifying low profitability per unit of shareholders funds

With a growth in Net Sales of 6.41%, the company declared Very Positive results in Mar 26

The company has declared positive results for the last 4 consecutive quarters
NET PROFIT(HY) At USD 53.41 MM has Grown at 84.54%
ROCE(HY) Highest at 112.6%
NET SALES(Q) Highest at USD 204.92 MM

With ROE of 69.02%, it has a attractive valuation with a 7.83 Price to Book Value

Over the past year, while the stock has generated a return of 51.34%, its profits have risen by 1756.5% ; the PEG ratio of the company is 0

High Institutional Holdings at 76.5%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Their stake has increased by 0.57% over the previous quarter.

Market Beating performance in long term as well as near term

Along with generating 51.34% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to TG Therapeutics, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is TG Therapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

TG Therapeutics, Inc.

51.34%

4.94

47.49%

S&P 500

25.41%

1.92

13.25%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

261.47%

EBIT Growth (5y)

19.64%

EBIT to Interest (avg)

-23.08

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.13

Sales to Capital Employed (avg)

0.82

Tax Ratio

6.21%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

76.50%

ROCE (avg)

24.02%

ROE (avg)

8.40%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

7.83

EV to EBIT

41.97

EV to EBITDA

41.30

EV to Capital Employed

6.88

EV to Sales

8.40

PEG Ratio

0.01

Dividend Yield

ROCE (Latest)

16.38%

ROE (Latest)

69.02%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

22What is working for the Company

NET PROFIT(HY)

At USD 53.41 MM has Grown at 84.54%

ROCE(HY)

Highest at 112.6%

NET SALES(Q)

Highest at USD 204.92 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 0.83 times

-10What is not working for the Company

NET PROFIT(Q)

At USD 30.16 MM has Fallen at -73.03%

DEBT-EQUITY RATIO (HY)

Highest at 41.01 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.41 times

INTEREST(Q)

Highest at USD 7.67 MM

Here's what is working for TG Therapeutics, Inc.

Net Sales

Highest at USD 204.92 MM and Grown

In each period in the last five periods

MOJO Watch

Near term sales trend is very positive

Net Sales (USD MM)

Net Sales

At USD 204.92 MM has Grown at 33%

over average net sales of the previous four periods of USD 154.07 MM

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Inventory Turnover Ratio

Highest at 0.83 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Here's what is not working for TG Therapeutics, Inc.

Net Profit

At USD 30.16 MM has Fallen at -73.03%

over average net sales of the previous four periods of USD 111.81 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Interest

At USD 7.67 MM has Grown at 17.34%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Debt-Equity Ratio

Highest at 41.01 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio

Lowest at 2.41 times and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Interest

Highest at USD 7.67 MM

in the last five periods and Increased by 17.34% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)